Comparative Pharmacology
Head-to-head clinical analysis: CHIBROXIN versus CIPRO XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIBROXIN versus CIPRO XR.
CHIBROXIN vs CIPRO XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chibroxin (norfloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription.
1-2 drops of 0.3% ophthalmic solution into affected eye(s) every 2 hours while awake for the first 2 days, then every 4 hours for 5-7 days.
500 mg to 1000 mg orally once daily for 7 to 14 days; extended-release tablet must be swallowed whole and administered with food.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function. Prolonged to 12-24 hours in moderate renal impairment (CrCl 30-50 mL/min) and >24 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, allowing twice-daily dosing; due to extended-release formulation, ciprofloxacin is released over 24 hours.
Renal: 98% as unchanged drug; hepatic: 2% as minor metabolites. Biliary/fecal excretion negligible.
Renal excretion of unchanged drug accounts for approximately 40-50% of the dose; hepatic metabolism (glucuronidation, sulfation) produces active metabolites, and biliary/fecal elimination (via feces) accounts for 20-35% of the dose.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic